Invariant natural killer T cells and immunotherapy of cancer.
Fulltext:
69606.pdf
Embargo:
until further notice
Size:
540.8Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2008Source
Clinical Immunology, 129, 2, (2008), pp. 182-94ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Tumorimmunology
Journal title
Clinical Immunology
Volume
vol. 129
Issue
iss. 2
Page start
p. 182
Page end
p. 94
Subject
NCMLS 1: Immunity, infection and tissue repairAbstract
Invariant CD1d restricted natural killer T (iNKT) cells are regulatory cells that express a canonical TCR-Valpha-chain (Valpha24.Jalpha18 in humans and Valpha14.Jalpha18 in mice) which recognizes glycolipid antigens presented by the monomorphic CD1d molecule. They can secrete a wide variety of both pro-inflammatory and anti-inflammatory cytokines very swiftly upon their activation. Evidence for the significance of iNKT cells in human cancer has been ambiguous. Still, the (pre-)clinical findings reviewed here, provide evidence for a distinct contribution of iNKT cells to natural anti-tumor immune responses in humans. Furthermore, clinical phase I studies that are discussed here have revealed that the infusion of cancer patients with ligand-loaded dendritic cells or cultured iNKT cells is well tolerated. We thus underscore the potential of iNKT cell based immunotherapy in conjunction with established modalities such as surgery and radiotherapy, as adjuvant therapy against carcinomas.
This item appears in the following Collection(s)
- Academic publications [245400]
- Electronic publications [132943]
- Faculty of Medical Sciences [93207]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.